Survodutide 10 mg

Specification

Dual agonism at GLP-1R and GCGR

Survodutide addresses two metabolic receptors at once: the GLP-1 receptor and the glucagon receptor. In research this profile couples satiety and energy-turnover pathways in one ligand and supports comparison with monoagonists or GIP/GLP-1 triagonists. Cellular and preclinical models use Survodutide to map how the relative weight of both paths shows up in glucose uptake, lipolysis, and thermogenesis-related markers. Laboratories that buy Survodutide receive the GLP-1/glucagon dual agonist at 10 mg per vial.

Reconstitution and handling

In the laboratory the lyophilizate is reconstituted with a suitable sterile solvent. The solvent is added slowly along the vessel wall and the preparation is mixed gently until the powder has dissolved completely. The resulting solution is processed promptly and protected from direct light until use. Volume and target concentration are set by the laboratory in its own protocol.

In-vitro research

Survodutide serves as a reference ligand for competitive binding studies and functional assays at GLP-1R and GCGR. In cAMP assays both signalling paths can be followed in parallel. Metabolic cell models use the peptide to build concentration-response curves for glucose uptake, lipolysis, and energetic markers. The lyophilized form supports defined dilution series across several experimental days.

Quality and analytics

Each batch is tested for purity by HPLC; the content is ≥99 %. An identity check confirms the peptide backbone. Results are documented per batch and apply to all ten vials in the box. That supplies stable reference data for comparing measurement series and for the reproducibility of in-vitro experiments. The lyophilized powder dissolves clearly in a suitable sterile solvent and is suited to defined dilution series.